{
  "id": 5384647,
  "title": "BTIG raises Climb Bio stock price target to $32 on phase 1 data",
  "url": "https://urgent.news/2026/09/03/btig-raises-climb-bio-stock-price-target-to-32-on-phase-1-data",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T18:06:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/btig-raises-climb-bio-stock-price-target-to-32-on-phase-1-data-93CH-4888386"
  },
  "original_language": "en",
  "account": "BTIG has increased its price target for Climb Bio (CLYM) stock to $32, up from $20, as it maintained a Buy rating. The firm highlighted positive Phase 1 results for CLYM116, the drug candidate for IgA nephropathy. CLYM116 is being developed to be administered every 12 weeks and has shown potential in reducing IgA by around 55% at 12 weeks with a 320mg dose. The drug demonstrated rapid and sustained suppression of APRIL, with over 90% suppression through 10 weeks and more than 75% maintained through 12 weeks. BTIG estimates the IgAN commercial opportunity for CLYM116 to be over $20 billion in the U.S. alone, with approximately 200,000 potential patients. The company expects NAVIGATE-2 Phase 2 data in the first half of 2027 and a Phase 3 registrational study to begin in 2027. BTIG also raised its probability of success for CLYM116 to 70% from 65% and adjusted its modeled price for the drug to match the annual gross price of its competing therapy, VOYXACT, which has an annualized gross price of $390,000. Investors can access 10 additional InvestingPro Tips for a deeper understanding of CLYM.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "Seeking Alpha News",
        "title": "Climb Bio slips after early-stage trial data for kidney disease drug",
        "url": "https://urgent.news/2026/09/03/climb-bio-slips-after-early-stage-trial-data-for-kidney-disease-drug",
        "published": "2026-09-03T16:11:38.000Z"
      },
      {
        "outlet": "Investing.com",
        "title": "Baird raises Climb Bio stock price target to $25 on trial data",
        "url": "https://urgent.news/2026/09/03/baird-raises-climb-bio-stock-price-target-to-25-on-trial-data",
        "published": "2026-09-03T17:03:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}